Table 1 Baseline characteristics of the included studies
Study | Location | Date | Study type* | Sample size | XDR (%) | HIV (%) | Previous therapy (%) | Mean resistance |
|---|---|---|---|---|---|---|---|---|
Drobac et al [19] | Peru | 1999-2003 | RC | 27 | - | - | - | - |
Joseph et al [17] | India | 2006-2007 | PC | 38 | 0 | 0 | 100 | 3 · 6 |
Malla et al [22] | Nepal | 2005-2006 | RC | 175 | - | - | 93 | 3 · 7 |
Mitnick et al. [20] | Peru | 1996-1999 | RC | 75 | - | 1 · 3 | 100 | Median 6 |
Mitnick et al. [21] | Peru | 1999-2002 | RC | 651 | 7 · 4 | 1 · 4 | 65 | 5 · 3, 8 · 4 |
Oyieng’o et al. [24] | Kenya | 2008-2010 | RC | 8 | 0 | 50 | 100 | 3 · 1 |
Satti et al. [25] | Lesotho | 2007-2011 | RC | 5 | 0 | 60 | - | 2.8 |
Singla et al. [16] | India | 2002-2006 | RC | 126 | - | 0 | 100 | 3 |
Thomas et al. [18] | India | 1999-2003 | PC | 66 | 1 · 5 | - | 100 | 3 · 4 |
Tupasi et al. [23] | Philippines | 1999-2002 | RC | 117 | - | - | 96 | - |